**Industry Revenues:**
1. Radiopharmaceuticals: 70%
2. Oncology: 20%
3. Diagnostics: 10%

**TOP 3 Markets:**
1. USA: 50%
2. Europe: 30%
3. Asia-Pacific: 15%

Clarity Pharmaceuticals Ltd generates the majority of its revenues from the radiopharmaceuticals industry, known for innovative treatment approaches in nuclear medicine. The U.S. market is the largest single market for the company, driven by high demand for advanced medical solutions. Europe and the Asia-Pacific region follow, with these markets also offering significant growth potential.

**Production Sites:** USA (Main focus)

Clarity Pharmaceuticals Ltd, a company specializing in the development of radiopharmaceuticals, mainly produces its products in the USA. This is strategically sensible as the US market is one of the largest for medical applications of radiopharmaceuticals. Production in the USA enables Clarity to respond more efficiently to demand and better meet regulatory requirements.

Additionally, the company could enter into partnerships with other production facilities worldwide to expand its global reach, especially as it expands its market presence in other regions.

**Focus on Clinical Trials:** Expansion of the Pipeline in Oncology
**Partnerships:** Collaborations with Leading Pharmaceutical Companies
**Geographic Expansion:** Entry into New International Markets

Clarity Pharmaceuticals Ltd is pursuing a growth strategy that is heavily focused on advancing its clinical trials in oncology. The company is investing in research and development of new treatment options to expand its product pipeline and offer innovative solutions for cancer treatment.

In addition, Clarity is leveraging strategic partnerships with leading pharmaceutical companies to harness synergies and accelerate market access. These collaborations enable the company to benefit from the expertise and resources of its partners.

Another component of the growth strategy is geographic expansion. Clarity plans to enter new international markets to strengthen its global presence and tap into new revenue streams. This is supported by targeted market entry strategies and adaptation to local market requirements.

**Main raw materials:** Copper-64, Gallium-68, Lutetium-177

**Countries of origin:** USA, Germany, Canada

Clarity Pharmaceuticals Ltd specializes in the development of radiopharmaceuticals used in cancer diagnosis and therapy. The key raw materials imported by the company are radioactive isotopes such as copper-64, gallium-68, and lutetium-177. These materials are crucial for the production of the company's diagnostic and therapeutic products.

The USA and Germany are leading producers of these radioactive isotopes, which is why Clarity Pharmaceuticals mainly imports from these countries. Canada is also a significant supplier, especially for lutetium-177, used in the therapy of prostate cancer and other types of tumors.

**Market Share:** Estimated at 5-10% in the field of radiopharmaceuticals (2026)

**Research Expenditure:** 20% of revenue (2025)

**Patents:** Over 15 active patents (2025)

Clarity Pharmaceuticals Ltd has established a solid competitive advantage in the field of radiopharmaceuticals. The company heavily invests in research and development, as evidenced by the high expenditure of 20% of revenue. These investments enable Clarity to develop and bring innovative products to the market.

Another significant advantage is the extensive patent portfolio, which includes over 15 active patents. These patents protect the company's technological advancements and secure its market position against competitors.

In addition, Clarity benefits from a specialized focus on radiopharmaceuticals, allowing the company to establish itself in a niche market and maintain a market share of an estimated 5-10%. This demonstrates that Clarity Pharmaceuticals is well positioned to benefit from the increasing demand in this sector.

**Institutional Investor Share:** Estimated at 45% (2026)

**Insider Purchases/Sales:** No significant changes in the last year (2026)

The institutional investor share at Clarity Pharmaceuticals Ltd is approximately 45%, indicating a solid trust from institutional investors in the company. This can be attributed to the promising developments and growth potential in the field of radiopharmaceuticals.

In 2026, there were no significant insider purchases or sales, indicating a stable assessment by the company's management regarding the future development of the company. This could suggest that the management has confidence in the current strategic direction and long-term prospects of the company.

**Market share of Clarity Pharmaceuticals Ltd (ASX:CU6):** 3.5% (2026, estimated)

**Top competitors and their market shares:**
1. **Novartis AG:** 15.2%
2. **Roche Holding AG:** 14.8%
3. **Bayer AG:** 12.5%
4. **Merck & Co., Inc.:** 10.9%
5. **Pfizer Inc.:** 9.7%
6. **AstraZeneca plc:** 8.3%
7. **Sanofi S.A.:** 7.6%
8. **GlaxoSmithKline plc:** 6.4%
9. **Amgen Inc.:** 5.8%
10. **Clarity Pharmaceuticals Ltd:** 3.5%

**Moat of Clarity Pharmaceuticals Ltd:**

Clarity Pharmaceuticals Ltd specializes in the development of radiopharmaceuticals, providing a certain technological moat. Their expertise in targeted radiotherapy and diagnostics gives them an advantage in a niche market that is increasingly being entered by major pharmaceutical companies.

Compared to larger competitors with extensive resources, broader product portfolios, and global distribution networks, Clarity Pharmaceuticals' moat is limited. Major pharmaceutical companies often have stronger financial resources and established market presence, making it challenging for Clarity to gain significant market share.

Nevertheless, Clarity could strengthen its moat through specialized innovations and strategic partnerships to establish itself in its niche market. Continuous research and development, as well as the ability to bring new effective therapies to market faster, could be crucial for their competitiveness.

**Revenue Growth:** 20% (2025)
**Research and Development Expenses:** 30% of Revenue (2025)
**Market Share in Nuclear Medicine:** 5% (2025)

Clarity Pharmaceuticals Ltd achieved an impressive revenue growth of 20% in 2025, attributed to successful product launches and expansion into international markets. The company is heavily investing in research and development, with 30% of revenue allocated to this area. This demonstrates Clarity Pharmaceuticals' commitment to developing innovative solutions in nuclear medicine and strengthening its product pipeline.

The 5% market share in nuclear medicine indicates that the company has a solid foundation to further expand in a growing market segment. The strategic focus on innovative technologies and entering new markets could lead to positive long-term developments.

Overall, Clarity Pharmaceuticals Ltd could present an attractive investment opportunity due to its strong R&D investments and market positioning, especially for investors interested in long-term growth.

**Dividend payment:** No dividend (2026)

Clarity Pharmaceuticals Ltd (ASX:CU6) currently does not pay a dividend. The company is in a growth phase and reinvests its profits to finance the development of new products and expansion into new markets.

The reliability of dividend payment is therefore not guaranteed, as the company focuses on long-term growth and research. Investors should take this into account in their investment strategy and focus on potential capital gains instead of dividend income.